ZyVersa Therapeutics, Inc. (ZVSA) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−36.6x

Market Cap

$7.66M

MomentumView details →

1D Return

−0.20%

YTD Return

−26.12%

RSI (14)

43.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−36.6x

Market Cap

$7.66M

RSI (14)

43.5

MomentumView details →

1D Return

−0.20%

YTD Return

−26.12%

SummaryUpdated Mar 1, 2026

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) is a clinical-stage biopharmaceutical company founded and headquartered in Weston, Florida. The company went public in February 2022 and focuses on developing novel therapeutic treatments for renal (kidney) and inflammatory diseases. As a pre-revenue biotechnology company, ZyVersa is currently advancing two primary drug candidates through clinical development: VAR 200 for kidney diseases and IC 100 for inflammatory conditions.

Ask drillr about ZyVersa Therapeutics, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

173.38%

ROA (TTM)

−3.30%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+57.28%

FCF YoY

+46.00%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+50.71%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$0.22

EPS Surprise

—

Beats (12Q)

4/12

Next Q EPS Est

—

Avg Surprise (4Q)

25.78%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

−84.96x

Current Ratio

0.05x

Quick Ratio

0.05x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−24.49M

Op. CF (TTM)

−2.62B

Next earningsNov 18, 2026 →

Latest newsMore news →

No recent news for ZVSA.

Similar companies

AlphaTON Capital Corp.ALP Acurx Pharmaceuticals, Inc.ACXP Bolt Biotherapeutics, Inc.BOLT InMed Pharmaceuticals Inc.INM Alzamend Neuro, Inc.ALZN Creative Medical Technology Holdings, Inc.CELZ Find similar companies →

Latest newsMore news →

No recent news for ZVSA.